These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 20488917)

  • 1. Cost-effectiveness of targeting patients undergoing percutaneous coronary intervention for therapy with bivalirudin versus heparin monotherapy according to predicted risk of bleeding.
    Amin AP; Marso SP; Rao SV; Messenger J; Chan PS; House J; Kennedy K; Robertus K; Cohen DJ; Mahoney EM
    Circ Cardiovasc Qual Outcomes; 2010 Jul; 3(4):358-65. PubMed ID: 20488917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes.
    Pinto DS; Stone GW; Shi C; Dunn ES; Reynolds MR; York M; Walczak J; Berezin RH; Mehran R; McLaurin BT; Cox DA; Ohman EM; Lincoff AM; Cohen DJ;
    J Am Coll Cardiol; 2008 Nov; 52(22):1758-68. PubMed ID: 19022155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes.
    Schwenkglenks M; Brazier JE; Szucs TD; Fox KA
    Value Health; 2011 Jan; 14(1):24-33. PubMed ID: 21211483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.
    Cohen DJ; Lincoff AM; Lavelle TA; Chen HL; Bakhai A; Berezin RH; Jackman D; Sarembock IJ; Topol EJ
    J Am Coll Cardiol; 2004 Nov; 44(9):1792-800. PubMed ID: 15519009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative cost-effectiveness of anticoagulation with bivalirudin or heparin with and without a glycoprotein IIb/IIIa-receptor inhibitor in patients undergoing percutaneous coronary intervention in Sweden: a decision-analytic model.
    Borg S; Persson U; Allikmets K; Ericsson K
    Clin Ther; 2006 Nov; 28(11):1947-59. PubMed ID: 17213015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bleeding risk and outcomes of Bivalirudin versus Glycoprotein IIb/IIIa inhibitors with targeted low-dose unfractionated Heparin in patients having percutaneous coronary intervention for either stable or unstable angina pectoris.
    Steinberg DH; Shah P; Kinnaird T; Pinto Slottow TL; Roy PK; Okabe T; Bonello L; de Labriolle A; Smith KA; Torguson R; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2008 Jul; 102(2):160-4. PubMed ID: 18602514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
    Stone GW; White HD; Ohman EM; Bertrand ME; Lincoff AM; McLaurin BT; Cox DA; Pocock SJ; Ware JH; Feit F; Colombo A; Manoukian SV; Lansky AJ; Mehran R; Moses JW;
    Lancet; 2007 Mar; 369(9565):907-19. PubMed ID: 17368152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
    Feldman DN; Minutello RM; Bergman G; Moussa I; Wong SC
    Catheter Cardiovasc Interv; 2010 Oct; 76(4):513-24. PubMed ID: 20882655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
    White HD; Ohman EM; Lincoff AM; Bertrand ME; Colombo A; McLaurin BT; Cox DA; Pocock SJ; Ware JA; Manoukian SV; Lansky AJ; Mehran R; Moses JW; Stone GW
    J Am Coll Cardiol; 2008 Sep; 52(10):807-14. PubMed ID: 18755342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a US hospital.
    Olchanski N; Slawsky KA; Plent S; Kado C; Cyr PL
    Hosp Pract (1995); 2010 Nov; 38(4):138-46. PubMed ID: 21068538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost analysis of bivalirudin versus reference anticoagulants without GP IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention for acute coronary syndrome in routine clinical practice. Pompidou registry.
    Puymirat E; Cohen S; Védrenne G; Caruba T; Sabatier B; Danchin N; Durand E
    Ann Cardiol Angeiol (Paris); 2013 Apr; 62(2):89-94. PubMed ID: 23245394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.
    Stone GW; Ware JH; Bertrand ME; Lincoff AM; Moses JW; Ohman EM; White HD; Feit F; Colombo A; McLaurin BT; Cox DA; Manoukian SV; Fahy M; Clayton TC; Mehran R; Pocock SJ;
    JAMA; 2007 Dec; 298(21):2497-506. PubMed ID: 18056903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in percutaneous peripheral intervention: a single-center experience.
    Sheikh IR; Ahmed SH; Mori N; Gupta A; Mewissen M; Allaqaband S; Bajwa T
    JACC Cardiovasc Interv; 2009 Sep; 2(9):871-6. PubMed ID: 19778776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of bivalirudin in patients with diabetes mellitus undergoing percutaneous coronary intervention in current clinical practice.
    Kim LK; Wong SC; Minutello RM; Bergman G; Feldman DN
    J Invasive Cardiol; 2010 Mar; 22(3):94-100. PubMed ID: 20197573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
    White HD; Chew DP; Hoekstra JW; Miller CD; Pollack CV; Feit F; Lincoff AM; Bertrand M; Pocock S; Ware J; Ohman EM; Mehran R; Stone GW
    J Am Coll Cardiol; 2008 May; 51(18):1734-41. PubMed ID: 18452778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Bivalirudin versus Bivalirudin plus glycoprotein IIb/IIIa inhibitor versus heparin plus glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes having percutaneous intervention for narrowed saphenous vein aorto-coronary grafts (the ACUITY trial investigators).
    Kumar D; Dangas G; Mehran R; Kirtane A; Bertrand M; Ebrahimi R; Guagliumi G; Brar S; Fahy M; Heller E; Moses J; Stone G
    Am J Cardiol; 2010 Oct; 106(7):941-5. PubMed ID: 20854954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical Appraisal of Bivalirudin versus Heparin for Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Trials.
    Bavry AA; Elgendy IY; Mahmoud A; Jadhav MP; Huo T
    PLoS One; 2015; 10(5):e0127832. PubMed ID: 26010682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin Versus Bivalirudin in Contemporary Percutaneous Coronary Intervention: A Welcome Back to an Old Friend Unfractionated Heparin.
    Centurión OA
    Crit Pathw Cardiol; 2015 Jun; 14(2):62-6. PubMed ID: 26102015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents.
    Feldman DN; Wong SC; Gade CL; Gidseg DS; Bergman G; Minutello RM
    Am Heart J; 2007 Oct; 154(4):695-701. PubMed ID: 17892994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction.
    Schwenkglenks M; Toward TJ; Plent S; Szucs TD; Blackman DJ; Baumbach A
    Heart; 2012 Apr; 98(7):544-51. PubMed ID: 22313548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.